End payors oppose Takeda motion to dismiss 'abandoned' US antitrust claims
MLex Summary: End-payor plaintiffs suing Takeda over an allegedly unlawful scheme to delay generic competition for its name-brand drug Amitiza partially opposed the company's motion to dismiss supposedly "abandoned" monopolization and...To view the full article, register now.
Already a subscriber? Click here to view full article